What Is Niemann Pick Type C Causes Symptoms Treatment?

Niemann-Pick type C (NPC) is a rare genetic disorder that disrupts how cells process cholesterol and other fats. This causes harmful buildup inside cells, especially in the brain, liver, and spleen. The disease affects coordination, thinking, and movement, and symptoms can appear from infancy through adulthood. There is no cure, but treatments can slow progression and improve quality of life.

What Is Niemann Pick Type C Causes Symptoms Treatment?

Niemann-Pick type C is caused by mutations in either the NPC1 or NPC2 gene. These genes provide instructions for proteins that help transport cholesterol and other lipids out of lysosomes — the cell’s recycling compartments. When the proteins don’t work correctly, cholesterol and fats build up inside cells, damaging them over time. The brain, liver, and spleen are most affected.

NPC is inherited in an autosomal recessive pattern. This means a child must inherit a mutated copy of the gene from each parent to develop the disease. Carriers — people with only one mutation — typically do not have symptoms.

Symptoms vary widely depending on the age when the disease begins. In infants, the first sign may be a prolonged yellowing of the skin and eyes (cholestatic jaundice) and an enlarged liver or spleen. In older children and adults, neurological symptoms often appear first. Key neurological signs include:

• Vertical gaze palsy — difficulty moving the eyes up and down
• Clumsiness and unsteady gait (ataxia)
• Slurred or slow speech (dysarthria)
• Trouble swallowing (dysphagia)
• Gradual loss of cognitive function
• Seizures in some cases
• Movement problems such as tremors or muscle stiffness

Some individuals also experience psychiatric symptoms such as depression, anxiety, or psychosis, especially when the disease begins in adolescence or adulthood.

Treatment focuses on slowing neurological damage and managing symptoms. The only drug approved for NPC in several countries — including the European Union, Canada, and Japan — is miglustat (brand name Zavesca). Miglustat is a substrate reduction therapy that works by reducing the buildup of certain fats in cells. In the United States, miglustat is not FDA-approved for NPC, but some doctors prescribe it off-label based on available evidence. Clinical studies suggest it can slow the progression of neurological symptoms, but it cannot reverse damage that has already occurred.

Supportive care is also essential. This includes physical therapy for movement problems, speech therapy for communication and swallowing difficulties, and medications for seizures or psychiatric symptoms. Nutritional support — such as a feeding tube when swallowing becomes unsafe — can help maintain weight and prevent pneumonia from food entering the lungs. Regular monitoring by a team of specialists is recommended.

Research is ongoing into new treatments, including gene therapy, enzyme replacement, and other small molecules. Some are in clinical trials, but none has been proven effective yet.

How Is Niemann-Pick Type C Inherited?

NPC is an autosomal recessive disorder. That means both parents must carry a mutation in the same NPC gene — either NPC1 or NPC2 — and pass it on to their child. If both parents are carriers, each pregnancy has a 1 in 4 chance of having a child with NPC. Around 95% of cases are caused by mutations in NPC1; the remaining 5% are due to NPC2 mutations.

Carrier status itself does not cause health problems. Genetic testing can identify carriers and is available for families with a history of the disease.

What Are the First Signs of Niemann-Pick Type C?

The first signs depend on the age of onset. For infants, the earliest clue may be a prolonged jaundice beyond the first few weeks of life, along with an enlarged liver and spleen. Some infants also have a buildup of fluid in the lungs (interstitial lung disease) that causes breathing problems.

In toddlers and older children, the first symptoms are often motor problems — such as falling frequently, trouble walking, or difficulty with fine motor skills. Vertical gaze palsy — the inability to voluntarily look up and down — is considered a hallmark sign, though it can be hard to spot in young children.

For adolescents and adults, the first signs may be clumsiness, speech changes, or psychiatric issues like depression or paranoia. Because these symptoms are common in other conditions, a diagnosis of NPC is often delayed by years.

How Is Niemann-Pick Type C Diagnosed?

Diagnosis begins with a physical exam and medical history, especially if there are known cases in the family. Key tests include:

• Filipin staining: A skin biopsy is taken and the cells are stained with a dye that shows cholesterol buildup. This is a standard diagnostic test. In NPC cells, the lysosomes glow brightly because of trapped cholesterol.
• Genetic testing: Sequencing the NPC1 and NPC2 genes confirms the diagnosis and identifies the specific mutations. This is the most definitive test.
• Biomarker tests: Blood tests looking for elevated levels of certain cholesterol byproducts (like cholestane-triol) can support the diagnosis but are not yet a replacement for genetic testing.

Prenatal testing is possible when the family mutations are known. Newborn screening is not yet standard for NPC, though research in this area is ongoing.

What Is the Outlook for People With Niemann-Pick Type C?

NPC is a progressive disease, meaning symptoms worsen over time. The rate of progression varies greatly depending on the age symptoms first appear. Infants with severe liver disease may not survive the first year. Children with early neurological onset often die in late childhood or early adolescence. People with later onset — teen or adult — can live into their 30s, 40s, or beyond. There is no way to predict the exact course for any individual.

Treatment with miglustat may slow neurological decline, especially if started early. Supportive care improves quality of life and can extend survival by preventing complications like pneumonia from aspiration.

Is There a Cure for Niemann-Pick Type C?

No cure currently exists. Miglustat and supportive care are the main management strategies. Researchers are studying gene therapy, which aims to deliver a working copy of the defective gene to cells. Early animal studies have shown promise, but human trials are still in early phases. Other experimental approaches include cyclodextrin therapy to help clear cholesterol from cells and histone deacetylase (HDAC) inhibitors that may improve NPC protein function. None of these has received regulatory approval.

Because NPC is so rare, clinical trials face challenges with recruiting enough participants. However, patient registries and advocacy groups are helping to accelerate research.